BRIEF-Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes

NewcelX

NewcelX

NCEL

0.00

May 27 (Reuters) - NewcelX AG NCEL.O:

  • SUBMITS PRE-IND PACKAGE TO THE FDA FOR NCEL-101 FOR THE TREATMENT OF TYPE 1 DIABETES

  • PRE-IND MEETING WITH FDA SCHEDULED TO ADVANCE NCEL-101 TO FIRST-IN-HUMAN TRIAL

  • TYPE B PRE-IND MEETING WITH FDA SCHEDULED FOR LAST WEEK OF JUNE

Source text: ID:nGNXc0HPBK

Further company coverage: NCEL.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.